Literature DB >> 22174368

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Alexander M Lesokhin1, Tobias M Hohl, Shigehisa Kitano, Czrina Cortez, Daniel Hirschhorn-Cymerman, Francesca Avogadri, Gabrielle A Rizzuto, John J Lazarus, Eric G Pamer, Alan N Houghton, Taha Merghoub, Jedd D Wolchok.   

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that accumulate during tumor formation, facilitate immune escape, and enable tumor progression. MDSCs are important contributors to the development of an immunosuppressive tumor microenvironment that blocks the action of cytotoxic antitumor T effector cells. Heterogeneity in these cells poses a significant barrier to studying the in vivo contributions of individual MDSC subtypes. Herein, we show that granulocyte-macrophage colony stimulating factor, a cytokine critical for the numeric and functional development of MDSC populations, promotes expansion of a monocyte-derived MDSC population characterized by expression of CD11b and the chemokine receptor CCR2. Using a toxin-mediated ablation strategy to target CCR2-expressing cells, we show that these monocytic MDSCs regulate entry of activated CD8 T cells into the tumor site, thereby limiting the efficacy of immunotherapy. Our results argue that therapeutic targeting of monocytic MDSCs would enhance outcomes in immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22174368      PMCID: PMC3288305          DOI: 10.1158/0008-5472.CAN-11-1792

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Colony-stimulating factors in inflammation and autoimmunity.

Authors:  John A Hamilton
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

Review 2.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

3.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Authors:  Kiavash Movahedi; Martin Guilliams; Jan Van den Bossche; Rafael Van den Bergh; Conny Gysemans; Alain Beschin; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

4.  GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients.

Authors:  Jens Atzpodien; Martina Reitz
Journal:  Cancer Biother Radiopharm       Date:  2007-08       Impact factor: 3.099

5.  Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Je-In Youn; Srinivas Nagaraj; Michelle Collazo; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

6.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Yasushi Sawanobori; Satoshi Ueha; Makoto Kurachi; Takeshi Shimaoka; James E Talmadge; Jun Abe; Yusuke Shono; Masahiro Kitabatake; Kazuhiro Kakimi; Naofumi Mukaida; Kouji Matsushima
Journal:  Blood       Date:  2008-03-28       Impact factor: 22.113

7.  GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.

Authors:  Andrew D Simmons; Betty Li; Melissa Gonzalez-Edick; Carol Lin; Marina Moskalenko; Thomas Du; Jennifer Creson; Melinda J VanRoey; Karin Jooss
Journal:  Cancer Immunol Immunother       Date:  2007-04-05       Impact factor: 6.968

Review 8.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Authors:  Miguel-Angel Perales; Jianda Yuan; Sarah Powel; Humilidad F Gallardo; Teresa S Rasalan; Christina Gonzalez; Gregor Manukian; Jian Wang; Yan Zhang; Paul B Chapman; Susan E Krown; Philip O Livingston; Samuel Ejadi; Katherine S Panageas; Manuel E Engelhorn; Stephanie L Terzulli; Alan N Houghton; Jedd D Wolchok
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

10.  Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; Yuelei Shen; Dan R Littman; James P Allison
Journal:  J Exp Med       Date:  2008-08-25       Impact factor: 14.307

View more
  160 in total

1.  Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Authors:  Dominic E Sanford; Brian A Belt; Roheena Z Panni; Allese Mayer; Anjali D Deshpande; Danielle Carpenter; Jonathan B Mitchem; Stacey M Plambeck-Suess; Lori A Worley; Brian D Goetz; Andrea Wang-Gillam; Timothy J Eberlein; David G Denardo; Simon Peter Goedegebuure; David C Linehan
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

2.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

Review 3.  Immunotherapy for lung cancer: advances and prospects.

Authors:  Li Yang; Liping Wang; Yi Zhang
Journal:  Am J Clin Exp Immunol       Date:  2016-03-23

Review 4.  ITCH as a potential therapeutic target in human cancers.

Authors:  Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2020-03-10       Impact factor: 15.707

5.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection.

Authors:  Cortney E Heim; Debbie Vidlak; Tyler D Scherr; Curtis W Hartman; Kevin L Garvin; Tammy Kielian
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

7.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

8.  Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.

Authors:  M Thorn; P Guha; M Cunetta; N J Espat; G Miller; R P Junghans; S C Katz
Journal:  Cancer Gene Ther       Date:  2016-05-20       Impact factor: 5.987

9.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.